Mereo BioPharma (MREO) Accumulated Expenses (2022 - 2026)

Mereo BioPharma (MREO) has reported Accumulated Expenses for 5 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 30.22% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 30.22% YoY), while the FY2025 annual figure was $2.0 million, down 50.23% from the prior year.
• Accumulated Expenses advanced to $2.0 million in Q1 2026 per MREO's latest filing, from $2.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.5 million in Q4 2023 and bottomed at $2.0 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $3.7 million across 5 years, with a median of $3.7 million in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 35.47% in 2025 and fell as far as 50.23% in 2025.
• Mereo BioPharma's Accumulated Expenses stood at $5.4 million in 2022, then gained by 0.57% to $5.5 million in 2023, then fell by 25.54% to $4.1 million in 2024, then tumbled by 50.23% to $2.0 million in 2025, then climbed by 0.99% to $2.0 million in 2026.
• Business Quant data shows MREO's Accumulated Expenses at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $4.1 million in Q3 2025.